or both lower limbs. Neurological symptoms, if present, are often subtle. 11 Vague abdominal discomfort, early satiety, and a change in bowel/bladder habits are possible. The onset of symptoms is generally insidious; the patient most frequently complains of a slowly progressive problem over several months.
Diagnostic Workup
After obtaining a thorough patient history, the physician should conduct a complete physical examination including abdominal, neurological, spine, and rectal vault assessment. Plain radiography frequently fails to reveal the true extent of the disease (Fig. 1 upper) . Axial CT scanning ( Fig. 1 center) or, preferably, magnetic resonance imaging ( Fig. 1 lower) is necessary for a full evaluation of the anatomical characteristic of the tumor and its invasion into surrounding structures. Bone scintigraphy demonstrates nonspecific increased activity but is recommended in the workup and staging of GCT 5 as well as other aggressive sacral tumors to evaluate noncontiguous disease. Multilevel spinal involvement has been reported in cases of GCT. 6 Furthermore, these lesions have been reported as a purely soft-tissue mass involving only the sacral canal without osseous involvement. 15 A staged biopsy procedure is appropriate. Pathological evaluation of the tissue specimen will reveal a large number of osteoclastic giant cells, admixed intimately with clusters and a scattered population of mononuclear cells. Mitotic figures are generally absent (Fig. 2) .
Behaviorial Features
Giant cell tumor has a 1 to 5% incidence of metastasizing to the lung. Recurrent tumors are at a significantly increased risk. Accordingly, pulmonary staging is an important component in the initial and follow-up evaluation of GCT of bone. Generally, lung metastases are late onset; their mean interval to progression is 4 years. The prognosis for survival when lung metastases develop is favorable in more than 70% of patients. Although surgical management of the metastatic lesions is the mainstay of treatment, some metastatic foci may resolve spontaneously. Nevertheless, in such cases approximately 15% of patients with metastatic disease may die (Fig. 3 ). 13 Giant cell tumor can convert to a fulminate malignant variant associated with a very poor prognosis. 2 In such cases the disease can become widely metastatic, spreading to locations beyond the lung, including bone, liver, spleen, and other viscera. Some authors have speculated that this is caused by radiotherapy. A conversion rate of 15 to 20% has been reported in patients in whom radiotherapy had involved greater than 3000-cGy doses of radiation, and conversion occurred 3 or more years after treatment. The conversion rate in patients who have not undergone irradiation is less than 5%. This has come into question with newer radiotherapy modalities. 
Treatment Options
The standard treatment for the GCT is curettage and placement of a bone graft or bone cement. Recurrence rates have been reported to be as high as 50% or greater when the intralesional resection is not carefully performed. Follow-up treatment for recurrent disease consists of an aggressive resection and reconstruction involving a large osteoarticular allograft, cementation, endoprosthesis, or an excision-induced arthrodesis. Currently, most surgeons elect to undertake an aggressive curettage fol- lowed by adjuvant phenol, hydrogen peroxide, liquid nitrogen, or argon beam therapy. 1, 9, 12 Cementation may serve as a local adjuvant while also restoring mechanical integrity to a compromised region, facilitating spinal and/ or pelvic fixation. In the sacrum, adjuvants must be used with caution to minimize inflicting trauma on the sacral nerve roots. Nerve root monitoring may be appropriate.
When GCT involves an expendable bone such as the proximal fibula or ilium, it should be primarily resected; however, this is generally not recommended for the sacrum. En bloc resection continues to be performed for multiple recurrent tumors, intensive soft-tissue involvement, or massively destructive lesions.
In appropriately selected patients, sacrectomy is a valuable procedure to effect local tumor control and overall patient survival, despite potential complications as well as neurological and sexual dysfunction (Fig. 4) . 12, 16 If such an operation is undertaken, it may necessitate an interdisciplinary surgical team including orthopedic oncology, general surgery, and spine surgery depending on the extent of the resection. Preoperative embolization should be considered because these tumors are highly vascular (Fig.  5) . A combined anterior-posterior approach is necessary for tumors with anterior extension and/or significant involvement of the S-1 and S-2 segments. 10 Reconstruction involving segmental spinal instrumentation and an allograft or prosthesis may be necessary after total sacrectomy (Fig. 6 ). An alternative to a conventional transperitoneal anterior approach is the extensile ilioinguinal approach, which permit simultaneous visualization of the anterior and posterior sacrum when combined with a posterior midline approach.
14 Embolization may also prove palliative and/or curative in cases in which the lesion cannot be resected or in which the disease is refractory to other treatments; the risk of local recurrence is equal to 31% at 10 years and 43% at 15 and 20 years. 7, 8 In cases of advanced multiple recurrent or aggressive metastatic disease, investigators are developing experimental medical protocols. Close follow-up evaluation for locally recurrent disease and pulmonary involvement is critical. Surveillance should include radiographic examination of the chest every 6 to 12 months for at least the first 2 to 3 years.
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